Journal of Drug Metabolism & Toxicology · 2012 · 121 citations · 56 references
PharmacyPharmacologyPharmacotherapyCancer PharmacologyRenal PharmacokineticsRenal PharmacotherapyMedication Side Effect ManagementPharmacokinetics In Renal ImpairmentRenal ToxicityToxicity ManagementHigh-dose Methotrexate PharmacokineticsHigh-dose Methotrexate TherapyInterindividual Absorption VariabilityInterindividual Bioavailability VariabilityMedication-related NephrotoxicityMethotrexate NephrotoxicityRenal Adverse EffectsRenal Clearance Variability
Methotrextae (MTX) is an antifolate first developed to treat certain types of cancer. It was used at higher doses as a cancer therapy and since 1990 it is used at much lower doses to treat rheumatic diseases [1]. Side effects of MTX high dose (MTX-HD) may be life threatening, however those of various doses of oral MTX are variable because of the interindividual variability of gastrointestinal absorption of this drug. Bone marrow, gastrointestinal mucosa and hair are particularly vulnerable to the effects of MTX, secondary to their high rate of cellular turnover [2] and because MTX concentration is inversly proportianal to renal clearance [2], renal toxicity is frequent with MTX-HD.
56
Bruce N. Cronstein, Dwight Naime, Edward Ostad · Journal of Clinical Investigation · 1993 · 678 citations · Full text
Medicine, Immunology, Pharmacology +16
Annelies E. van Ede, Roland Laan, M. J. Rood et al. · Arthritis & Rheumatism · 2001 · 399 citations
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis
Sergio Gutiérrez‐Ureña, José Fernando Molina, M L Cuéllar et al. · Arthritis & Rheumatism · 1996 · 280 citations
METHOTREXATE-INDUCED PNEUMONITIS
H. Dirk Sostman, Richard A. Matthay, Charles E. Putman et al. · Medicine · 1976 · 271 citations